Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I
US11124501B2 · kind B2 · utility
2Cited by
8References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 6, 2018 |
| Grant date | Sep 21, 2021 |
| Priority date | — |
| Expiry date | Dec 6, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D491/056
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.